| Year |
Citation |
Score |
| 2020 |
Reis PP, Tokar T, Goswami RS, Xuan Y, Sukhai M, Seneda AL, Móz LES, Perez-Ordonez B, Simpson C, Goldstein D, Brown D, Gilbert R, Gullane P, Irish J, Jurisica I, ... Kamel-Reid S, et al. A 4-gene signature from histologically normal surgical margins predicts local recurrence in patients with oral carcinoma: clinical validation. Scientific Reports. 10: 1713. PMID 32015424 DOI: 10.1038/S41598-020-58688-Y |
0.324 |
|
| 2020 |
Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, ... ... Kamel-Reid S, et al. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31992589 DOI: 10.1158/1078-0432.Ccr-19-2576 |
0.316 |
|
| 2020 |
Nikbakht H, Jessa S, Sukhai MA, Arseneault M, Zhang T, Letourneau L, Thomas M, Bourgey M, Roehrl MHA, Eveleigh R, Chen EX, Krzyzanowska M, Moore MJ, Giesler A, Yu C, ... ... Kamel-Reid S, et al. Latency and interval therapy affect the evolution in metastatic colorectal cancer. Scientific Reports. 10: 581. PMID 31953485 DOI: 10.1038/S41598-020-57476-Y |
0.363 |
|
| 2020 |
Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D, McNamara C, Murphy T, Shuh AC, Yee K, Sibai H, Minden MD, Wei C, Stockley T, Kamel-Reid S, et al. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica. PMID 31896684 DOI: 10.3324/Haematol.2019.235721 |
0.35 |
|
| 2019 |
Malone ER, Saleh RR, Yu C, Ahmed L, Pugh T, Torchia J, Bartlett J, Virtanen C, Hotte SJ, Hilton J, Welch S, Robinson A, McCready E, Lo B, Sadikovic B, ... ... Kamel-Reid S, et al. OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing. Current Oncology (Toronto, Ont.). 26: e618-e623. PMID 31708655 DOI: 10.3747/Co.26.5235 |
0.357 |
|
| 2019 |
Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, et al. Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. Blood Advances. 3: 2307-2311. PMID 31371380 DOI: 10.1182/Bloodadvances.2019000306 |
0.322 |
|
| 2019 |
Moncur JT, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Kim AS. Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee. Archives of Pathology & Laboratory Medicine. PMID 30969158 DOI: 10.5858/Arpa.2018-0396-Cp |
0.328 |
|
| 2019 |
Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. Gynecologic Oncology. PMID 30792002 DOI: 10.1016/J.Ygyno.2019.02.005 |
0.333 |
|
| 2019 |
Perdrizet K, Stockley T, Law JH, Shabir M, Zhang T, Le LW, Lau A, Tsao MS, Pal P, Cabanero M, Ko H, Schwock J, Kamel-Reid S, Liu G, Sacher AG, et al. Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model. Journal of Clinical Oncology. 37: 2620-2620. DOI: 10.1200/Jco.2019.37.15_Suppl.2620 |
0.362 |
|
| 2019 |
Campbell PA, Thavorn K, Lo B, Karimnezhad A, Perkins TJ, Urquhart R, Kamel-Reid S, Sekhon H, Stewart DJ. Abstract 3355: Challenges in the implementation of molecular diagnostic testing for non-small cell lung cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3355 |
0.303 |
|
| 2019 |
Rose AAN, Armstrong SM, Hogg D, Butler M, Joshua AM, Ghazarian D, Kamel-Reid S, Habeeb AA, Chappell MA, Ross K, Amir E, Bedard PL, Siu L, Spreafico A. Abstract 3141: The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3141 |
0.31 |
|
| 2018 |
Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. Clinical Lung Cancer. PMID 30770327 DOI: 10.1016/J.Cllc.2018.12.009 |
0.367 |
|
| 2018 |
Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL. Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. The Journal of Molecular Diagnostics : Jmd. PMID 30576869 DOI: 10.1016/J.Jmoldx.2018.09.008 |
0.318 |
|
| 2018 |
McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, ... ... Kamel-Reid S, et al. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Advances. 2: 2658-2671. PMID 30327374 DOI: 10.1182/Bloodadvances.2018021469 |
0.386 |
|
| 2018 |
Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, ... Kamel-Reid S, et al. Additional germline findings from a tumor profiling program. Bmc Medical Genomics. 11: 65. PMID 30092803 DOI: 10.1186/S12920-018-0383-5 |
0.328 |
|
| 2018 |
Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 123: 22-29. PMID 30089591 DOI: 10.1016/J.Lungcan.2018.06.023 |
0.369 |
|
| 2018 |
Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A. Evidence-based best practices for T790M testing in lung cancer in Canada. Current Oncology (Toronto, Ont.). 25: 163-169. PMID 29719432 DOI: 10.3747/Co.25.4044 |
0.373 |
|
| 2018 |
Kavanagh S, Heath E, Hurren R, Gronda M, Barghout SH, Liyanage SU, Siriwardena TP, Claudio J, Zhang T, Sukhai M, Stockley TL, Kamel-Reid S, Rostom A, Lutynski A, Khalaf D, et al. AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. Leukemia Research. 68: 22-28. PMID 29518628 DOI: 10.1016/J.Leukres.2018.02.012 |
0.363 |
|
| 2018 |
Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN. Standardizing biomarker testing for Canadian patients with advanced lung cancer. Current Oncology (Toronto, Ont.). 25: 73-82. PMID 29507487 DOI: 10.3747/Co.25.3867 |
0.366 |
|
| 2018 |
Chua M, Murgic J, Hosni A, Salcedo A, Kamel-Reid S, Berlin A, Pintile M, Fraser M, Van Der Kwast T, Boutros PC, Bristow RG. A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer. Journal of Clinical Oncology. 36: 68-68. DOI: 10.1200/Jco.2018.36.6_Suppl.68 |
0.308 |
|
| 2018 |
Perdrizet K, Stockley T, Tsao MS, Morganstein J, Kamel-Reid S, Ranich L, Shepherd FA, Liu G, Bradbury PA, Hwang D, Pal P, Schwock J, Boerner SL, Law JH, Leighl NB. Upfront next generation sequencing in NSCLC: A publicly funded perspective. Journal of Clinical Oncology. 36: 12062-12062. DOI: 10.1200/Jco.2018.36.15_Suppl.12062 |
0.323 |
|
| 2018 |
Daher-Reyes GS, McNamara CJ, Maganti M, Stockley TL, Capo-Chichi JM, Alkharras RA, Arruda A, Claudio J, Chan SM, Schimmer AD, Minden MD, Sibai H, Yee KW, Gupta V, Kamel-Reid S, et al. Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience Blood. 132: 2666-2666. DOI: 10.1182/Blood-2018-99-118938 |
0.416 |
|
| 2018 |
Murphy T, Zou J, Daher-Reyes GS, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Stockley TL, Kamel-Reid S, Maze D, Bratman S, Schuh A, Chan SM. Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations Blood. 132: 992-992. DOI: 10.1182/Blood-2018-99-115518 |
0.406 |
|
| 2018 |
Puckrin R, Atenafu EG, Claudio J, Chan SM, Gupta V, Maze D, McNamara CJ, Minden MD, Schuh A, Murphy T, Sibai H, Yee KW, Stockley TL, Kamel-Reid S, Schimmer AD. Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML Blood. 132: 436-436. DOI: 10.1182/Blood-2018-99-113090 |
0.381 |
|
| 2018 |
Murphy T, Zou J, Daher-Reyes GS, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KW, Stockley TL, Kamel-Reid S, Maze D, Bratman S, Schuh A, Chan SM. Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations Blood. 132: 992-992. DOI: 10.1016/J.Clml.2019.07.113 |
0.411 |
|
| 2017 |
Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, Sukhai M, Thomas M, Bartoszko J, Ho J, Siddiq N, Maze D, Schimmer A, Schuh A, Sibai H, ... ... Kamel-Reid S, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Advances. 1: 1729-1738. PMID 29296819 DOI: 10.1182/Blood.V128.22.4263.4263 |
0.391 |
|
| 2017 |
Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology. 44: 187-197. PMID 29248130 DOI: 10.1053/J.Seminoncol.2017.08.004 |
0.371 |
|
| 2017 |
Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, et al. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Research and Treatment. PMID 29177603 DOI: 10.1007/S10549-017-4580-2 |
0.334 |
|
| 2017 |
Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, ... ... Kamel-Reid S, et al. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clinical Colorectal Cancer. PMID 29128266 DOI: 10.1016/J.Clcc.2017.10.010 |
0.323 |
|
| 2017 |
Lewin J, Garg S, Lau BY, Dickson BC, Traub F, Gokgoz N, Griffin AM, Ferguson PC, Andrulis IL, Sim HW, Kamel-Reid S, Stockley TL, Siu L, Wunder JS, Ra Razak A. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. International Journal of Cancer. PMID 28891048 DOI: 10.1002/Ijc.31039 |
0.366 |
|
| 2017 |
Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, et al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 111: 23-29. PMID 28838393 DOI: 10.1200/Jco.2016.34.15_Suppl.11585 |
0.364 |
|
| 2017 |
O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 109: 137-144. PMID 28577943 DOI: 10.1016/J.Lungcan.2017.04.016 |
0.358 |
|
| 2017 |
Thomas M, Sukhai MA, Zhang T, Dolatshahi R, Harbi D, Garg S, Misyura M, Pugh T, Stockley TL, Kamel-Reid S. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies. Archives of Pathology & Laboratory Medicine. 141: 759-775. PMID 28557600 DOI: 10.5858/Arpa.2016-0547-Ra |
0.318 |
|
| 2017 |
Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T, Li Z, Liu J, Mansour M, Masih-Khan E, Zhang T, Bratman SV, Oza AM, Kamel-Reid S, Trudel S, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nature Communications. 8: 15086. PMID 28492226 DOI: 10.1038/Ncomms15086 |
0.325 |
|
| 2017 |
Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Current Oncology (Toronto, Ont.). 24: 111-119. PMID 28490925 DOI: 10.3747/Co.24.3524 |
0.387 |
|
| 2017 |
Lim C, Sekhon HS, Cutz JC, Hwang DM, Kamel-Reid S, Carter RF, Santos GDC, Waddell T, Binnie M, Patel M, Paul N, Chung T, Brade A, El-Maraghi R, Sit C, et al. Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario. Current Oncology (Toronto, Ont.). 24: 103-110. PMID 28490924 DOI: 10.3747/Co.24.3495 |
0.322 |
|
| 2017 |
Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, ... ... Kamel-Reid S, et al. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer. PMID 28475299 DOI: 10.1002/Cncy.21868 |
0.352 |
|
| 2017 |
Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, et al. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28363487 DOI: 10.1016/J.Radonc.2017.03.007 |
0.309 |
|
| 2017 |
Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding KV, Nikiforova MN. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. The Journal of Molecular Diagnostics : Jmd. PMID 28341590 DOI: 10.1016/J.Jmoldx.2017.01.011 |
0.305 |
|
| 2017 |
Ko HM, Saieg MA, da Cunha Santos G, Kamel-Reid S, Boerner SL, Geddie WR. Use of cytological samples of metastatic melanoma for ancillary studies. Cytopathology : Official Journal of the British Society For Clinical Cytology. PMID 28217853 DOI: 10.1111/Cyt.12419 |
0.322 |
|
| 2017 |
Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC, Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, et al. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecologic Oncology. PMID 28062115 DOI: 10.1016/J.Ygyno.2016.12.002 |
0.349 |
|
| 2017 |
Kim D, Bence-Bruckler I, Forrest DL, Savoie L, Couban S, Busque L, Delage R, Laneuville P, Liew E, Xenocostas A, Paulson K, Kamel-Reid S, Lipton JH, Leber B. Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD) Blood. 130: 1622-1622. DOI: 10.1182/Blood.V130.Suppl_1.1622.1622 |
0.328 |
|
| 2017 |
Stjepanovic N, Kim R, Wilson M, Mandilaras V, Berman H, Amir E, Cescon D, Elser C, Armel SR, McCuaig J, Volenik A, Demsky R, Chow H, Misyura M, Wang L, ... ... Kamel-Reid S, et al. Abstract P3-09-05: Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-09-05 |
0.384 |
|
| 2017 |
Stjepanovic N, Garg S, Berman H, Warr D, Amir E, Cescon D, Elser C, Wang L, Kamel-Reid S, Siu L, Bedard P, Stockley T. Abstract P2-05-19: Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P2-05-19 |
0.343 |
|
| 2017 |
Kis O, Chow S, Kaedbey R, Danesh A, Dowar M, Li T, Li Z, Liu J, Masih-Khan E, Mulder D, Zhang T, Bratman S, Oza A, Kamel-Reid S, Pugh T, et al. Targeted Sequencing of Circulating Cell-free DNA in Multiple Myeloma Allows Analysis of Somatic Mutations, Copy Number Aberrations, and Translocations Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.03.167 |
0.324 |
|
| 2016 |
Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, ... ... Kamel-Reid S, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine. 8: 109. PMID 27782854 DOI: 10.1186/S13073-016-0364-2 |
0.348 |
|
| 2016 |
Misyura M, Zhang T, Sukhai MA, Thomas M, Garg S, Kamel-Reid S, Stockley TL. Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics. The Journal of Molecular Diagnostics : Jmd. 18: 842-850. PMID 27770852 DOI: 10.1016/J.Jmoldx.2016.06.004 |
0.323 |
|
| 2016 |
White-Al Habeeb N, Kulasingam V, Diamandis EP, Yousef GM, Tsongalis GJ, Vermeulen L, Zhu Z, Kamel-Reid S. The Use of Targeted Therapies for Precision Medicine in Oncology. Clinical Chemistry. PMID 27679436 DOI: 10.1373/Clinchem.2015.247882 |
0.367 |
|
| 2016 |
Deotare U, Shaheen M, Brandwein JM, Pitcher B, Kamel-Reid S, Yee KW, Schimmer A, Minden MD, Gupta V, Schuh AC. Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. Hematological Oncology. PMID 27597292 DOI: 10.1002/Hon.2341 |
0.324 |
|
| 2016 |
Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, et al. Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. Current Oncology (Toronto, Ont.). 23: 196-200. PMID 27330348 DOI: 10.3747/Co.23.3120 |
0.391 |
|
| 2016 |
Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, De Perrot M, Shepherd FA, et al. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget. PMID 27028852 DOI: 10.18632/Oncotarget.8350 |
0.306 |
|
| 2016 |
Martin P, Shiau CJ, Pasic M, Tsao M, Kamel-Reid S, Lin S, Tudor R, Cheng S, Higgins B, Burkes R, Ng M, Arif S, Ellis PM, Hubay S, Kuruvilla S, et al. Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. British Journal of Cancer. PMID 26889973 DOI: 10.1038/Bjc.2016.22 |
0.374 |
|
| 2016 |
da Cunha Santos G, Wyeth T, Reid A, Saieg MA, Pitcher B, Pintilie M, Kamel-Reid S, Tsao MS. A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. Journal of Clinical Pathology. PMID 26733659 DOI: 10.1136/Jclinpath-2015-203437 |
0.336 |
|
| 2016 |
Fallah-Rad N, Bedard PL, Siu LL, Kamel-Reid S, Chow H, Weijiang Z, Jang R, Krzyzanowska MK, Razak ARA, Chen EX. Association of isocitrate dehydorgenase-1 (IDH-1) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer. Journal of Clinical Oncology. 34: 627-627. DOI: 10.1200/Jco.2016.34.4_Suppl.627 |
0.324 |
|
| 2016 |
Doherty M, Chiu JW, McNamara MG, Horgan AM, Serra S, Kamel-Reid S, Zhang T, Bedard PL, Hedley DW, Dhani NC, Jang RW, Knox JJ. Molecular profiling of advanced biliary cancer: Lost in translation from bench to bedside. Journal of Clinical Oncology. 34: 283-283. DOI: 10.1200/Jco.2016.34.4_Suppl.283 |
0.424 |
|
| 2016 |
Doherty M, Korpanty G, Tomasini P, Alizadeh M, Jao K, Labbe C, Mascaux C, Martin P, Kamel-Reid S, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, et al. Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E20527 |
0.31 |
|
| 2016 |
Mandilaras V, Lheureux S, Stjepanovic N, Burnier J, Wilson MK, Wang L, Clarke B, Shaw PA, Berman HK, Kim R, Armel SR, McCuaig J, Volenik A, Ahmed L, Misyura M, ... ... Kamel-Reid S, et al. Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome. Journal of Clinical Oncology. 34: 5579-5579. DOI: 10.1200/Jco.2016.34.15_Suppl.5579 |
0.345 |
|
| 2016 |
Freixinos VR, Lheureux S, Mandilaras V, Clarke B, Dhani N, Mackay H, Butler M, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard P, Oza AM. Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients. Journal of Clinical Oncology. 34: 5509-5509. DOI: 10.1200/Jco.2016.34.15_Suppl.5509 |
0.328 |
|
| 2016 |
Stjepanovic N, Bedard PL, Oza AM, Clarke B, Krzyzanowska MK, Jang RW, Dhani NC, Leighl NB, Gupta AA, Elser C, McCuaig J, Aronson M, Holter S, Semotiuk K, Ahmed L, ... ... Kamel-Reid S, et al. Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients. Journal of Clinical Oncology. 34: 1532-1532. DOI: 10.1200/Jco.2016.34.15_Suppl.1532 |
0.35 |
|
| 2016 |
Law AD, Sukhai MA, Thomas M, Arruda A, Ibrahimova N, Chan SM, Gupta V, Minden MD, Schimmer AD, Sibai H, Yee KW, Barber DL, Stockley TL, Kamel-Reid S, Schuh AC. Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations Blood. 128: 2886-2886. DOI: 10.1182/Blood.V128.22.2886.2886 |
0.412 |
|
| 2016 |
Kim DDH, Bence-Bruckler I, Forrest DL, Savoie ML, Couban S, Busque L, Delage R, Laneuville P, Liew E, Xenocostas A, Paulson K, Kamel-Reid S, Lipton JH, Leber B. Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial Blood. 128: 1922-1922. DOI: 10.1182/Blood.V128.22.1922.1922 |
0.352 |
|
| 2016 |
Bedard PL, Oza A, Clarke B, Tsao M, Leighl NB, Chen EX, Razak A, Berman HK, Serra S, Roehrl M, Califaretti N, Trinkaus M, Zhang T, Sukhai MA, Milea A, ... ... Kamel-Reid S, et al. Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pmsclingen15-Pr03 |
0.407 |
|
| 2016 |
Aung KL, Pugh TJ, Stockley T, Wang L, Korpanty G, Serra S, Shaw P, Tsao MS, Dhani N, Mackay H, Shepherd FA, Kamel-Reid S, Siu LL, Bedard PL. Abstract 02: Pan-cancer analysis of hotspot mutations in genes encoding the members of mitogen activated protein kinase (MAPK) and phosphoinosidtide-3 kinase (PI3K) pathways among smokers and non-smokers Clinical Cancer Research. 22: 2-2. DOI: 10.1158/1557-3265.Pmsclingen15-02 |
0.358 |
|
| 2016 |
Mahe E, Mulder D, Dowar M, Sukhai M, Nguyen L, Ohashi P, Delabie J, Stockley TL, Pugh T, Kamel-Reid S. Abstract 846: Improving T-cell receptor clonotyping of T-cell lymphomas using hybrid-Capture and next-generation sequencing Cancer Research. 76: 846-846. DOI: 10.1158/1538-7445.Am2016-846 |
0.312 |
|
| 2016 |
Garg S, Sukhai MA, Misyura M, Thomas M, Zhang T, Siu LL, Bedard PL, Stockley TL, Kamel-Reid S. Abstract 4765: Impact of TP53 status and functional classification on molecular profiles in breast cancer subtypes Cancer Research. 76: 4765-4765. DOI: 10.1158/1538-7445.Am2016-4765 |
0.32 |
|
| 2016 |
Stjepanovic N, Wilson M, Mandilaras V, Clarke B, Berman H, Kim RH, Lheureux S, Armel SR, McCuaig J, Volenik A, Demsky R, Chow H, Mysura M, Siu L, Bedard P, ... Kamel-Reid S, et al. Germline and somatic multi-gene sequencing in patients (pts) with advanced high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw392.28 |
0.323 |
|
| 2015 |
Rouzbahman M, Kamel-Reid S, Al Habeeb A, Butler M, Dodge J, Laframboise S, Murphy J, Rasty G, Ghazarian D. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis-A Single-Center Study. Journal of Lower Genital Tract Disease. 19: 350-3. PMID 26225944 DOI: 10.1097/Lgt.0000000000000142 |
0.35 |
|
| 2015 |
Lim C, Tsao MS, Le LW, Shepherd FA, Feld R, Burkes RL, Liu G, Kamel-Reid S, Hwang D, Tanguay J, da Cunha Santos G, Leighl NB. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer†. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1415-21. PMID 25922063 DOI: 10.1093/Annonc/Mdv208 |
0.372 |
|
| 2015 |
Sukhai MA, Craddock KJ, Thomas M, Hansen AR, Zhang T, Siu L, Bedard P, Stockley TL, Kamel-Reid S. A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 25880439 DOI: 10.1038/Gim.2015.47 |
0.302 |
|
| 2015 |
Chiu JW, Serra S, Kamel-Reid S, Zhang T, McNamara MG, Bedard PL, Hedley DW, Moore MJ, Dhani NC, Shek T, Kwong Y, Yau TC, Doherty M, Knox JJ. Next-generation sequencing: Profiling gallbladder cancer (GBC). Journal of Clinical Oncology. 33: 286-286. DOI: 10.1200/Jco.2015.33.3_Suppl.286 |
0.375 |
|
| 2015 |
Korpanty G, Kamel-Reid S, Tsao MS, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Gill B, Pintilie M, Shepherd FA. Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre. Journal of Clinical Oncology. 33: e19006-e19006. DOI: 10.1200/Jco.2015.33.15_Suppl.E19006 |
0.386 |
|
| 2015 |
Tomasini P, Sung M, Kamel-Reid S, Tsao MS, Liu G, Bradbury PA, Shepherd FA, Feld R, Leighl NB. EGFR mutations in NSCLC: Does ethnicity influence outcomes? Journal of Clinical Oncology. 33: e17633-e17633. DOI: 10.1200/Jco.2015.33.15_Suppl.E17633 |
0.377 |
|
| 2015 |
Jao K, Tomasini P, Kamel-Reid S, Tsao MS, Korpanty GJ, Mascaux C, Liu G, Leighl NB, Feld R, Bradbury PA, Ennis M, Shepherd FA. Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 7521-7521. DOI: 10.1200/Jco.2015.33.15_Suppl.7521 |
0.385 |
|
| 2015 |
Wilson MK, Bedard PL, Joshua AM, Mackay H, Butler MO, Dhani NC, Lheureux S, Martin-Lorente C, Rodriguez-Freixinos V, Clarke B, Shaw P, Milea A, Wang L, Kamel-Reid S, Stockley T, et al. Molecular profiling and targeted therapy in advanced endometrial cancer. Journal of Clinical Oncology. 33: 5589-5589. DOI: 10.1200/Jco.2015.33.15_Suppl.5589 |
0.36 |
|
| 2015 |
Stjepanovic N, Wilson MK, Oza AM, Clarke B, Berman HK, Amir E, Mackay H, Shaw P, Butler MO, Mulligan AM, Milea A, Ahmed L, Volenik A, Wang L, Pugh TJ, ... ... Kamel-Reid S, et al. Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status. Journal of Clinical Oncology. 33: 1532-1532. DOI: 10.1200/Jco.2015.33.15_Suppl.1532 |
0.365 |
|
| 2015 |
Tomasini P, Jao K, Kamel-Reid S, Stockley T, Tsao MS, Liu G, Leighl NB, Feld R, Bradbury PA, Pintilie M, Mascaux C, Shepherd FA. Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 11060-11060. DOI: 10.1200/Jco.2015.33.15_Suppl.11060 |
0.39 |
|
| 2015 |
Kamel-Reid S, Thomas M, Sukhai MA, Barber DL, Garg S, Misyura M, Dolatshahi R, Harbi D, Zhang T, Porwit A, Delabie JM, Ibrahimova N, Shanavas M, Yee KW, Pugh TJ, et al. Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care Blood. 126: 3848-3848. DOI: 10.1182/Blood.V126.23.3848.3848 |
0.371 |
|
| 2015 |
Sukhai MA, Thomas M, Craddock KJ, Zhang T, Stockley TL, Kamel-Reid S. Abstract A2-38: Interpretation and classification system for somatic variants identified in solid tumor molecular profiling Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A2-38 |
0.349 |
|
| 2015 |
Garg S, Sukhai MA, Thomas M, Mah M, Zhang T, Pugh T, Kamel-Reid S, Stockley TL. Abstract 628: Determinants of quality of next-generation sequencing output from the strand-specific TruSight Tumor Sequencing Panel in a clinical diagnostic setting Cancer Research. 75: 628-628. DOI: 10.1158/1538-7445.Am2015-628 |
0.304 |
|
| 2015 |
Kaedbey R, Kis O, Danesh A, Dowar M, Li T, Li Z, Liu J, Mansour M, Sukhai M, Zhang T, Kamel-Reid S, Pugh TJ, Trudel S. Abstract 615: Noninvasive diagnosis of actionable mutations by deep sequencing of circulating tumor DNA in multiple myeloma Cancer Research. 75: 615-615. DOI: 10.1158/1538-7445.Am2015-615 |
0.388 |
|
| 2015 |
Thomas M, Sukhai M, Zhang T, Harbi D, Souza JD, MacDonald K, Pugh T, Minden M, Schuh A, Stockley TL, Kamel-Reid S. Abstract 4260: Clinical testing and implementation of the TruSight Myeloid Next Generation Sequencing (NGS) panel for identification of clinically relevant variants in hematological malignancies Cancer Research. 75: 4260-4260. DOI: 10.1158/1538-7445.Am2015-4260 |
0.398 |
|
| 2015 |
Bruce JP, Danesh A, Winegarden N, Yau P, Virtanen C, Kamel-Reid S, Roehrl MH, Joshua AM, Knox J, Pugh TJ. Abstract 3898: Exome analysis of an exceptional responder uncovers an activating GNAS mutation that may confer sensitivity to cytotoxic chemotherapy Cancer Research. 75: 3898-3898. DOI: 10.1158/1538-7445.Am2015-3898 |
0.317 |
|
| 2015 |
Mahe ER, Pugh T, Stockley T, Kamel-Reid S. Abstract 3708: Filling the void of Canadian T-cell lymphoma epidemiology: Data from the canadian institute for health information discharge abstract database Cancer Research. 75: 3708-3708. DOI: 10.1158/1538-7445.Am2015-3708 |
0.303 |
|
| 2015 |
Kaedbey R, Kis O, Danesh A, Dowar M, Li T, Li ZH, Liu J, Mansour M, Sukhai M, Zhang T, Kamel-Reid S, Kukreti V, Reece D, Chen C, Tiedemann R, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM) Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.180 |
0.312 |
|
| 2014 |
Hansen A, Geddie W, Boerner S, Ghai S, Berman H, Serra S, Roehrl M, Joshua AM, Oza AM, Moore M, Amir E, Usmani T, Giesler A, Amin N, Zhang T, ... ... Kamel-Reid S, et al. 1612PFINE NEEDLE BIOPSIES ARE FEASIBLE AS A MINIMALLY INVASIVE MEANS FOR TARGETED NEXT GENERATION SEQUENCING IN ADVANCED SOLID TUMORS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv558. PMID 28172381 DOI: 10.1093/Annonc/Mdu358.43 |
0.351 |
|
| 2014 |
Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, Allo G, Tsao MS, Kamel-Reid S, Eisenhauer EA, Oza AM. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic Oncology. 135: 184-9. PMID 25173583 DOI: 10.1016/J.Ygyno.2014.06.033 |
0.329 |
|
| 2014 |
Blanchette PS, Spreafico A, Miller FA, Chan K, Bytautas J, Kang S, Bedard PL, Eisen A, Potanina L, Holland J, Kamel-Reid S, McPherson JD, Razak AR, Siu LL. Genomic testing in cancer: patient knowledge, attitudes, and expectations. Cancer. 120: 3066-73. PMID 24962202 DOI: 10.1002/Cncr.28807 |
0.328 |
|
| 2014 |
Shiau CJ, Babwah JP, da Cunha Santos G, Sykes JR, Boerner SL, Geddie WR, Leighl NB, Wei C, Kamel-Reid S, Hwang DM, Tsao MS. Sample features associated with success rates in population-based EGFR mutation testing. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 947-56. PMID 24922009 DOI: 10.1097/Jto.0000000000000196 |
0.373 |
|
| 2014 |
Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, Tran-Thanh D, Gill S, Dhani N, Au HJ, Wang L, Moore MJ. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. European Journal of Cancer (Oxford, England : 1990). 50: 1909-15. PMID 24857345 DOI: 10.1016/J.Ejca.2014.04.008 |
0.39 |
|
| 2014 |
Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, et al. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Investigational New Drugs. 32: 1005-16. PMID 24788563 DOI: 10.1007/S10637-014-0106-5 |
0.332 |
|
| 2014 |
Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. American Journal of Hematology. 89: 626-32. PMID 24619861 DOI: 10.1002/Ajh.23707 |
0.315 |
|
| 2014 |
Cervigne NK, Machado J, Goswami RS, Sadikovic B, Bradley G, Perez-Ordonez B, Galloni NN, Gilbert R, Gullane P, Irish JC, Jurisica I, Reis PP, Kamel-Reid S. Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? Human Molecular Genetics. 23: 2618-28. PMID 24403051 DOI: 10.1093/Hmg/Ddt657 |
0.304 |
|
| 2014 |
Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology. 164: 223-32. PMID 24383843 DOI: 10.1111/Bjh.12618 |
0.331 |
|
| 2014 |
Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim DD, Uhm J, Lambie A, Ellis L, Lipton JH. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clinical Lymphoma, Myeloma & Leukemia. 14: 87-92. PMID 24252361 DOI: 10.1016/J.Clml.2013.09.010 |
0.364 |
|
| 2014 |
Chiu JW, Bedard PL, Roehrl MH, Serra S, Kryzanowska MK, Knox JJ, Mackay H, Hedley DW, Moore MJ, Liu G, Dhani NC, Kamel-Reid S, Torlakovic E, Wang T, Tsao M, et al. Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience. Journal of Clinical Oncology. 32: 459-459. DOI: 10.1200/Jco.2014.32.3_Suppl.459 |
0.368 |
|
| 2014 |
Lim CH, Le L, Shepherd FA, Feld R, Burkes RL, Liu G, Kamel-Reid S, Tsao MS, Leighl NB. Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer. Journal of Clinical Oncology. 32: 6595-6595. DOI: 10.1200/Jco.2014.32.15_Suppl.6595 |
0.39 |
|
| 2014 |
Spreafico A, Oza AM, Clarke B, Mackay H, Shaw P, Rasty G, Butler MO, Dhani NC, Lheureux S, Wilson M, Welch S, Siu LL, Zhang T, Yu C, Krishna GD, ... ... Kamel-Reid S, et al. Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 32: 5506-5506. DOI: 10.1200/Jco.2014.32.15_Suppl.5506 |
0.372 |
|
| 2014 |
Graham DM, Arseneault M, Sukhai MA, Letourneau L, Karimzadeh M, Zhang T, Thomas M, Roehrl MHA, Chen EX, Krzyzanowska MK, Moore MJ, Giesler A, Yu C, Bedard PL, Kamel-Reid S, et al. Analysis of clonal evolution in colorectal cancer. Journal of Clinical Oncology. 32: 3510-3510. DOI: 10.1200/Jco.2014.32.15_Suppl.3510 |
0.35 |
|
| 2014 |
Chow S, Pendergrast JM, Ochoa-Garay G, Gupta V, Munir ME, Wei C, Craddock KJ, Kamel-Reid S, Cserti-Gazdewich C. Mixed Fields on RHD Typing As an Indicator of Malignancy-Associated Loss of Heterozygosity on Chromosome 1p in Myeloid Neoplasm Blood. 124: 5105-5105. DOI: 10.1182/Blood.V124.21.5105.5105 |
0.327 |
|
| 2014 |
Deotare U, Shaheen M, Brandwein JM, Gill B, Kamel-Reid S, Yee KW, Rydlewski A, Lutynski A, Rostom A, Schimmer AD, Minden MD, Gupta V, Seftel MD, Alam N, Schuh AC. Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis Blood. 124: 3693-3693. DOI: 10.1182/Blood.V124.21.3693.3693 |
0.362 |
|
| 2014 |
Sukhai MA, Thomas M, Zhang T, Wei C, Trudel S, Yee K, Minden MD, Schuh A, Stockley T, Kamel-Reid S. Abstract 4713: High-throughput multiplex Sequenom MassARRAY clinical diagnostic assay for the identification of actionable genetic variants in hematologic malignancies Cancer Research. 74: 4713-4713. DOI: 10.1158/1538-7445.Am2014-4713 |
0.402 |
|
| 2013 |
Reaume MN, Graham GE, Tomiak E, Kamel-Reid S, Jewett MA, Bjarnason GA, Blais N, Care M, Drachenberg D, Gedye C, Grant R, Heng DY, Kapoor A, Kollmannsberger C, Lattouf JB, et al. Canadian guideline on genetic screening for hereditary renal cell cancers. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 7: 319-23. PMID 24319509 DOI: 10.5489/Cuaj.1496 |
0.305 |
|
| 2013 |
Press RD, Kamel-Reid S, Ang D. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. The Journal of Molecular Diagnostics : Jmd. 15: 565-76. PMID 23810242 DOI: 10.1016/J.Jmoldx.2013.04.007 |
0.329 |
|
| 2013 |
Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Human Pathology. 44: 2038-46. PMID 23701943 DOI: 10.1016/J.Humpath.2013.03.007 |
0.347 |
|
| 2013 |
Kim DD, Lee H, Kamel-Reid S, Lipton JH. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. British Journal of Haematology. 160: 630-9. PMID 23278256 DOI: 10.1111/Bjh.12187 |
0.337 |
|
| 2013 |
Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Caplan S, Foo A, Walsh W, Leber B. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leukemia & Lymphoma. 54: 760-6. PMID 23061485 DOI: 10.3109/10428194.2012.737917 |
0.379 |
|
| 2013 |
Tran B, Brown AM, Bedard PL, Winquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, Ghai S, ... ... Kamel-Reid S, et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. International Journal of Cancer. Journal International Du Cancer. 132: 1547-55. PMID 22948899 DOI: 10.1002/Ijc.27817 |
0.405 |
|
| 2013 |
Dang H, Jiang A, Kamel-Reid S, Brandwein J, Chang H. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Human Pathology. 44: 55-61. PMID 22939316 DOI: 10.1016/J.Humpath.2012.04.008 |
0.36 |
|
| 2013 |
Martin P, Shiau CJ, Pasic MD, Tsao MS, Kamel-Reid S, Le L, Higgins BP, Cheng SY, Burkes RL, Ng M, Arif S, Roxana T, Lin SCX, Ellis PM, Hubay S, et al. Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC. Journal of Clinical Oncology. 31: e19077-e19077. DOI: 10.1200/Jco.2013.31.15_Suppl.E19077 |
0.384 |
|
| 2013 |
Shiau CJ, Babwah JP, Santos GDC, Sykes JR, Boerner SL, Geddie WR, Wei C, Kamel-Reid S, Hwang DM, Tsao MS. Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E19032 |
0.338 |
|
| 2013 |
Hansen AR, Brown AMK, Bedard PL, Hotte SJ, Winquist E, Goss GD, Vergidis D, Hirte HW, Welch S, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, ... ... Kamel-Reid S, et al. Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program. Journal of Clinical Oncology. 31: 11016-11016. DOI: 10.1200/Jco.2013.31.15_Suppl.11016 |
0.369 |
|
| 2013 |
Bedard PL, Oza AM, Tsao M, Leighl NB, Shepherd FA, Chen EX, Tannock I, Krzyzanowska MK, Dhani NC, Clarke B, Berman HK, Serra S, Craddock KJ, Chadwick D, Zhang T, ... ... Kamel-Reid S, et al. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). Journal of Clinical Oncology. 31: 11002-11002. DOI: 10.1200/Jco.2013.31.15_Suppl.11002 |
0.396 |
|
| 2013 |
Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim DDH, Uhm J, Lambie A, Ellis L, Lipton JH. A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation Blood. 122: 5501-5501. DOI: 10.1182/Blood.V122.21.5501.5501 |
0.364 |
|
| 2013 |
How J, Sykes J, Minden MD, Gupta V, Yee KWL, Schimmer AD, Schuh AC, Kamel-Reid S, Brandwein JM. The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics Blood Cancer Journal. 3. DOI: 10.1038/Bcj.2013.14 |
0.385 |
|
| 2012 |
Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 120: 3898-905. PMID 22915637 DOI: 10.1182/Blood-2012-02-410688 |
0.328 |
|
| 2012 |
Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S. Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Current Oncology (Toronto, Ont.). 19: S33-44. PMID 22787409 DOI: 10.3747/Co.19.1149 |
0.348 |
|
| 2012 |
Kamel-Reid S, Chong G, Ionescu DN, Magliocco AM, Spatz A, Tsao M, Weng X, Young S, Zhang T, Soulieres D. EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. Current Oncology (Toronto, Ont.). 19: e67-74. PMID 22514499 DOI: 10.3747/Co.19.862 |
0.378 |
|
| 2012 |
Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL. Cancer genomics: technology, discovery, and translation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 647-60. PMID 22271477 DOI: 10.1200/Jco.2011.39.2316 |
0.346 |
|
| 2012 |
Kamel-Reid S, Zhang T, Persons DL, Nikiforova MN, Halling KC. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Archives of Pathology & Laboratory Medicine. 136: 26-32. PMID 22208484 DOI: 10.5858/Arpa.2011-0220-Oa |
0.353 |
|
| 2012 |
You B, Le Tourneau C, Chen EX, Wang L, Jarvi A, Bharadwaj RR, Kamel-Reid S, Perez-Ordonez B, Mann V, Siu LL. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. American Journal of Clinical Oncology. 35: 255-60. PMID 21358293 DOI: 10.1097/Coc.0B013E31820Dbdcc |
0.325 |
|
| 2012 |
Kamel-Reid S, Zhang T, Persons DL, Nikiforova MN, Halling KC. Erratum: Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma (Archives of Pathology and Laboratory Medicine (2012) 136:1 (26-32)) Archives of Pathology & Laboratory Medicine. 136. DOI: 10.5858/1543-2165-136.10.1170 |
0.314 |
|
| 2012 |
Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Macdonald DR, Easaw JC, Eisenstat DD, Kakumanu AS, Squire J, Tsao MS, Kamel-Reid S, Tassignon A, Hausman DF, Mason WP. Phase II study of PX-866 in recurrent glioblastoma. Journal of Clinical Oncology. 30: 2051-2051. DOI: 10.1200/Jco.2012.30.15_Suppl.2051 |
0.32 |
|
| 2012 |
Kim DDH, Lee HG, Kamel-Reid S, Lipton JH. BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib. Blood. 120: 2777-2777. DOI: 10.1182/Blood.V120.21.2777.2777 |
0.335 |
|
| 2012 |
Brown AMK, Bedard PL, Tran B, Dancey J, Winquist E, Hotte SJ, Goss G, Welch S, Zhang T, Stein L, Ferretti V, Watt S, Jiao W, Ng K, Shaw P, ... ... Kamel-Reid S, et al. Abstract LB-230: A prospective clinical trial to evaluate DNA sequencing as a diagnostic tool to guide cancer therapy: results from the initial 50 patients Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-230 |
0.417 |
|
| 2011 |
Tsao MS, Ionescu D, Chong G, Magliocco AM, Soulieres D, Hwang D, Young S, Wei C, Bosdet I, Karsan A, Spatz A, Kamel-Reid S. Population-based pan-Canadian EGFR-mutation testing program. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e18017. PMID 28020105 DOI: 10.1200/Jco.2011.29.15_Suppl.E18017 |
0.35 |
|
| 2011 |
Reis PP, Waldron L, Perez-Ordonez B, Pintilie M, Galloni NN, Xuan Y, Cervigne NK, Warner GC, Makitie AA, Simpson C, Goldstein D, Brown D, Gilbert R, Gullane P, Irish J, ... ... Kamel-Reid S, et al. A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence. Bmc Cancer. 11: 437. PMID 21989116 DOI: 10.1186/1471-2407-11-437 |
0.311 |
|
| 2011 |
Aubin F, Gill S, Burkes R, Colwell B, Kamel-Reid S, Koski S, Pollett A, Samson B, Tehfe M, Wong R, Young S, Soulières D. Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. Current Oncology (Toronto, Ont.). 18: e180-4. PMID 21874108 DOI: 10.3747/Co.V18I4.779 |
0.359 |
|
| 2011 |
Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3278-85. PMID 21788564 DOI: 10.1200/Jco.2010.34.1578 |
0.343 |
|
| 2011 |
Brandwein JM, Hedley DW, Chow S, Schimmer AD, Yee KWL, Schuh AC, Gupta V, Xu W, Kamel-Reid S, Minden MD. A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: Inhibition of Akt activation correlates with complete response Leukemia. 25: 945-952. PMID 21403650 DOI: 10.1038/Leu.2011.34 |
0.339 |
|
| 2011 |
Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, Zhang T, Ludkovski O, Wang L, Chen EX, Tsao MS, Kamel-Reid S, Siu LL. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck Oncology. 3: 11. PMID 21352589 DOI: 10.1186/1758-3284-3-11 |
0.339 |
|
| 2011 |
Jiang A, Jiang H, Brandwein J, Kamel-Reid S, Chang H. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leukemia Research. 35: 492-8. PMID 20684989 DOI: 10.1016/J.Leukres.2010.07.021 |
0.357 |
|
| 2011 |
Hughes TP, Lipton JH, Leber B, Spector N, Cervantes F, Pasquini R, Clementino N, Schwarer AP, Mahon F, Rea D, Yeung DT, Kamel-Reid S, Bendit I, Reynolds J, Williams L, et al. Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib Blood. 118: 606-606. DOI: 10.1182/Blood.V118.21.606.606 |
0.312 |
|
| 2011 |
Razak AR, Bedard PL, You B, Panchal D, Chen EX, Ivy SP, Zhang W, Kamel-Reid S, Pham N, Zhang T, Hotte SJ, Reedijk M, Shimizu M, Ailles L, Haines C, et al. Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B50 |
0.344 |
|
| 2011 |
Tran B, Dancey JE, Bedard PL, Kamel-Reid S, McPherson JD, Stein LD, Brown AM, Zhang T, Watt S, Ferretti V, Ghai S, Petrocelli T, Shaw P, Neel BG, Onetto N, et al. Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B48 |
0.382 |
|
| 2011 |
Siu LL, Allo G, Pond GR, Zhang T, Ho J, Hotte SJ, Laurie SA, Singh S, Winquist E, Chia SKL, Chen EX, Chan KK, Mormont C, Quinn S, Wang T, ... ... Kamel-Reid S, et al. Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A50 |
0.361 |
|
| 2010 |
Kim DH, Sriharsha L, Jung CW, Kamel-Reid S, Radich JP, Lipton JH. Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter? American Journal of Hematology. 85: 856-62. PMID 20882527 DOI: 10.1002/Ajh.21850 |
0.311 |
|
| 2010 |
Soulières D, Greer W, Magliocco AM, Huntsman D, Young S, Tsao M-, Kamel-Reid S. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Current Oncology. 17. PMID 20680106 DOI: 10.3747/Co.V17Is1.614 |
0.36 |
|
| 2010 |
Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia & Lymphoma. 51: 252-60. PMID 20109071 DOI: 10.3109/10428190903585286 |
0.324 |
|
| 2010 |
Luo J, Qi C, Xu W, Kamel-Reid S, Brandwein J, Chang H. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. American Journal of Clinical Pathology. 133: 34-40. PMID 20023256 DOI: 10.1309/Ajcpci1Ffe2Drxiv |
0.364 |
|
| 2010 |
Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology. 65: 353-61. PMID 19499221 DOI: 10.1007/S00280-009-1041-6 |
0.319 |
|
| 2010 |
Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Foo A, Leber B. Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS). Journal of Clinical Oncology. 28: 6564-6564. DOI: 10.1200/Jco.2010.28.15_Suppl.6564 |
0.305 |
|
| 2010 |
Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M, Larson RA, Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ. A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial Blood. 116: LBA-6-LBA-6. DOI: 10.1182/Blood.V116.21.Lba-6.Lba-6 |
0.31 |
|
| 2010 |
Goswami RS, Barth D, Masih-Khan E, Sun H(, Mathew M, Chen C, Trudel S, Kamel-Reid S, Reece DE. Characteristics of Patients Presenting with Secondary Myelodysplastic Syndrome During Treatment with Lenalidomide for Relapsed/Refractory Multiple Myeloma: 5q Deletions Can Be Observed Blood. 116: 1876-1876. DOI: 10.1182/Blood.V116.21.1876.1876 |
0.311 |
|
| 2010 |
Sukhai MA, Thomas M, Xuan Y, Mahindra S, Zhang T, Reis PPd, Minden M, Kamel-Reid S. Abstract 5010: Nucleophosmin (NPM) is univerally deregulated in acute promyelocytic leukemia Cancer Research. 70: 5010-5010. DOI: 10.1158/1538-7445.Am10-5010 |
0.332 |
|
| 2010 |
Thomas M, Sukhai M, Schuh N, Xuan Y, Minden M, Kamel-Reid S. Abstract 1240: Functional deregulation of NF-kB and abnormal TNFa response in acute promyelocytic leukemia Cancer Research. 70: 1240-1240. DOI: 10.1158/1538-7445.Am10-1240 |
0.353 |
|
| 2009 |
Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4750-8. PMID 19584153 DOI: 10.1158/1078-0432.Ccr-09-0145 |
0.333 |
|
| 2009 |
Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KW, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. British Journal of Haematology. 146: 76-85. PMID 19438471 DOI: 10.1111/J.1365-2141.2009.07712.X |
0.314 |
|
| 2009 |
Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D, Weck K, Zehnder J. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. The Journal of Molecular Diagnostics : Jmd. 11: 4-11. PMID 19095773 DOI: 10.2353/Jmoldx.2009.080095 |
0.367 |
|
| 2009 |
Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 94: 135-9. PMID 19066329 DOI: 10.3324/Haematol.13151 |
0.321 |
|
| 2009 |
Kim DHD, Kong JH, Park S, Jung CW, Sriharsha L, Xu W, Kamel-Reid S, Kim Y, Kim H, Lipton JH. IFN-γ (interferon-gamma) Genotype Predict Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia. Blood. 114: 2178-2178. DOI: 10.1182/Blood.V114.22.2178.2178 |
0.332 |
|
| 2009 |
Ward R, Kamel-Reid S, Xu W, Minden MD, Schimmer AD, Yee KW, Schuh A, Gupta V, Brandwein J. Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye. Blood. 114: 1591-1591. DOI: 10.1182/Blood.V114.22.1591.1591 |
0.33 |
|
| 2009 |
Kim DH(, Kim JA, Yun J, Sriharsha L, Jang JH, Kim K, Jung CW, Kamel-Reid S, Radich J, Lipton JH. Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia. Blood. 114: 1110-1110. DOI: 10.1182/Blood.V114.22.1110.1110 |
0.306 |
|
| 2009 |
You B, Tourneau CL, Chen EX, Chin SF, Wang L, Jarvi A, Bharadwaj RR, Kamel-Reid S, Perez-Ordonez B, Siu LL. 8527 A phase II trial of erlotinib after gemcitabine plus platinum-based chemotherapy in patients (pts) with recurrent and/or metastatic nasopharyngeal carcinoma (NPC) Ejc Supplements. 7: 478-479. DOI: 10.1016/S1359-6349(09)71618-0 |
0.301 |
|
| 2008 |
Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8295-301. PMID 19088047 DOI: 10.1158/1078-0432.Ccr-08-0999 |
0.33 |
|
| 2008 |
Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 112: 3330-8. PMID 18684859 DOI: 10.1182/Blood-2008-04-150680 |
0.314 |
|
| 2008 |
Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4268-75. PMID 18626007 DOI: 10.1200/Jco.2007.14.8924 |
0.386 |
|
| 2008 |
Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer. 113: 772-81. PMID 18543309 DOI: 10.1182/Blood.V110.11.1950.1950 |
0.365 |
|
| 2008 |
Siegal D, Xu W, Sutherland R, Kamel-Reid S, Kuruvilla J, Lipton JH, Minden M, Messner H, Gupta V. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplantation. 42: 51-6. PMID 18372907 DOI: 10.1038/Bmt.2008.88 |
0.311 |
|
| 2008 |
Sukhai M, Thomas M, Goswami R, Xuan Y, Reis PPd, Kamel-Reid S. Deregulation of Transcription Factors GATA-1, GATA-2 and C/EBPa in Acute Promyelocytic Leukemia. Blood. 112: 2241-2241. DOI: 10.1182/Blood.V112.11.2241.2241 |
0.33 |
|
| 2007 |
Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, ... Kamel-Reid S, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2184-90. PMID 17538163 DOI: 10.1200/Jco.2006.07.6554 |
0.378 |
|
| 2007 |
Medeiros BC, Minden MD, Schuh AC, Schimmer AD, Yee K, Lipton JH, Messner HA, Gupta V, Chun K, Xu W, Das P, Kamel-Reid S, Brandwein JM. Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leukemia & Lymphoma. 48: 65-71. PMID 17325849 DOI: 10.1080/10428190601043252 |
0.33 |
|
| 2007 |
Medeiros BC, Chun K, Kamel-Reid S, Lipton J. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation. American Journal of Hematology. 82: 758-60. PMID 17301975 DOI: 10.1002/Ajh.20882 |
0.326 |
|
| 2007 |
Medeiros BC, Zhang T, Lipton JH, Kamel-Reid S. Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia. American Journal of Hematology. 82: 293-4. PMID 17013813 DOI: 10.1002/Ajh.20765 |
0.352 |
|
| 2007 |
Shepherd FA, Ding K, Sakurada A, Santos GDC, Zhu C, Seymour L, Whitehead M, Kamel-Reid S, Squire J, Tsao MS. Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer Journal of Clinical Oncology. 25: 7571-7571. DOI: 10.1200/Jco.2007.25.18_Suppl.7571 |
0.403 |
|
| 2007 |
Moore MJ, Santos GdC, Kamel-Reid S, Chin K, Tu D, Parulekar W, Ludkovski O, Squire J, Richardson F, Tsao M. The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3 Journal of Clinical Oncology. 25: 4521-4521. DOI: 10.1200/Jco.2007.25.18_Suppl.4521 |
0.359 |
|
| 2007 |
Kim DH(, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner H, Lipton J. Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia. Blood. 110: 737-737. DOI: 10.1182/Blood.V110.11.737.737 |
0.31 |
|
| 2006 |
Tremblay S, Pintor Dos Reis P, Bradley G, Galloni NN, Perez-Ordonez B, Freeman J, Brown D, Gilbert R, Gullane P, Irish J, Kamel-Reid S. Young patients with oral squamous cell carcinoma: study of the involvement of GSTP1 and deregulation of the Fanconi anemia genes. Archives of Otolaryngology--Head & Neck Surgery. 132: 958-66. PMID 16982972 DOI: 10.1001/Archotol.132.9.958 |
0.332 |
|
| 2006 |
Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 108: 28-37. PMID 16522812 DOI: 10.1182/Blood-2006-01-0092 |
0.36 |
|
| 2006 |
Tsao M, Zhu C, Sakurada A, Zhang T, Whitehead M, Kamel-Reid S, Ding K, Seymour L, Shepherd F. An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer Journal of Clinical Oncology. 24: 7005-7005. DOI: 10.1200/Jco.2006.24.18_Suppl.7005 |
0.366 |
|
| 2006 |
Khorashad JS, Lipton JH, Marin D, Milojkovic D, Cross NCP, Dibb N, Melo JV, Kamel-Reid S, Goldman JM, Apperley JF, Kaeda JS. Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment. Blood. 108: 2153-2153. DOI: 10.1182/Blood.V108.11.2153.2153 |
0.364 |
|
| 2005 |
Tsao MS, Sakurada A, Lorimer I, Cutz JC, Kamel-Reid S, Squire J, Ding K, Frank R, Seymour L, Shepherd F. Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7007. PMID 27943794 DOI: 10.1200/Jco.2005.23.16_Suppl.7007 |
0.373 |
|
| 2005 |
Audet N, Beasley NJ, MacMillan C, Jackson DG, Gullane PJ, Kamel-Reid S. Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer. Archives of Otolaryngology--Head & Neck Surgery. 131: 1065-70. PMID 16365219 DOI: 10.1001/Archotol.131.12.1065 |
0.328 |
|
| 2005 |
Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S, Tsang R, Yi QL, Minden M, Messner H, Kiss T. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 764-72. PMID 16182177 DOI: 10.1016/J.Bbmt.2005.06.006 |
0.323 |
|
| 2005 |
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. 353: 133-44. PMID 16014883 DOI: 10.1056/Nejmoa050736 |
0.378 |
|
| 2005 |
Brandwein JM, Gupta V, Wells RA, Schuh AC, Schimmer AD, Lipton JH, Messner HA, Yi QL, Chun K, Kamel-Reid S, Minden MD. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients. Leukemia Research. 29: 1381-6. PMID 15927253 DOI: 10.1016/J.Leukres.2005.04.020 |
0.352 |
|
| 2005 |
Mäkitie AA, Pintor Dos Reis P, Arora S, Macmillan C, Warner GC, Sukhai M, Dardick I, Perez-Ordonez B, Wells R, Brown D, Gilbert R, Freeman J, Gullane P, Irish J, Kamel-Reid S. Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model. Laboratory Investigation; a Journal of Technical Methods and Pathology. 85: 947-61. PMID 15880136 DOI: 10.1038/Labinvest.3700288 |
0.308 |
|
| 2005 |
Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. European Journal of Cancer (Oxford, England : 1990). 41: 523-30. PMID 15737556 DOI: 10.1016/J.Ejca.2004.12.013 |
0.319 |
|
| 2005 |
Abdelhameed AA, Brandwein JM, Chun K, Gupta V, Kamel-Reid S, Lipton JH, Minden MD, Schimmer AD, Schuh AC, Messner HA. Outcome of Patients with Secondary Leukemias Managed with Different Treatment Strategies at a Single Center. Blood. 106: 2249-2249. DOI: 10.1182/Blood.V106.11.2249.2249 |
0.34 |
|
| 2004 |
Shago M, Bouman D, Kamel-Reid S, Minden M, Chun K. Cryptic insertion of MLL gene into 9p22 leads to MLL-MLLT3 (AF9) fusion in a case of acute myelogenous leukemia. Genes, Chromosomes and Cancer. 40: 349-354. PMID 15188459 DOI: 10.1002/Gcc.20045 |
0.3 |
|
| 2004 |
Warner GC, Reis PP, Jurisica I, Sultan M, Arora S, Macmillan C, Makitie AA, Grénman R, Reid N, Sukhai M, Freeman J, Gullane P, Irish J, Kamel-Reid S. Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis. International Journal of Cancer. Journal International Du Cancer. 110: 857-68. PMID 15170668 DOI: 10.1002/Ijc.20197 |
0.339 |
|
| 2004 |
Gupta V, Yi QL, Brandwein J, Minden MD, Schuh AC, Wells RA, Chun K, Kamel-Reid S, Tsang R, Daly A, Kiss T, Lipton JH, Messner HA. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplantation. 33: 397-404. PMID 14688816 DOI: 10.1038/Sj.Bmt.1704368 |
0.318 |
|
| 2004 |
Gu C, Zheng HJ, Chan LS, Brandwein J, Kamel-Reid S, Minden MD, Schimmer AD, Schuh AC, Wells RA. Disordered Expression of HIPK Family Members in MDS and AML. Blood. 104: 4311-4311. DOI: 10.1182/Blood.V104.11.4311.4311 |
0.344 |
|
| 2004 |
Ichim CV, Sukhai MA, Brandwein J, Minden MD, Schimmer AD, Schuh AC, Kamel-Reid S, Iscove NN, Wells RA. EAR-2: Identification of a Gene Involved in Maintenance of Clonogenicity in Haematopoiesis. Blood. 104: 3226-3226. DOI: 10.1182/Blood.V104.11.3226.3226 |
0.323 |
|
| 2003 |
Kolomietz F, Marrano P, Yee K, Thai B, Braude I, Kolomietz A, Chun K, Minkin S, Kamel-Reid S, Minden M, Squire JA. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome Leukemia. 17: 1313-1323. PMID 12835719 DOI: 10.1038/Sj.Leu.2402969 |
0.318 |
|
| 2003 |
Gupta V, Kamel-Reid S, Minden MD, Lipton JH, Brandwein J, Messner HA. Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias. Hematology (Amsterdam, Netherlands). 8: 139-43. PMID 12745646 DOI: 10.1080/1024533031000134929 |
0.329 |
|
| 2002 |
Stulberg J, Kamel-Reid S, Chun K, Tokunaga J, Wells RA. Molecular Analysis of a New Variant of the CBFβ - MYH11 Gene Fusion Leukemia & Lymphoma. 43: 2021-2026. PMID 12481902 DOI: 10.1080/1042819021000015989-1 |
0.319 |
|
| 2002 |
Reis PP, Rogatto SR, Kowalski LP, Nishimoto IN, Montovani JC, Corpus G, Squire JA, Kamel-Reid S. Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene. 21: 6480-7. PMID 12226751 DOI: 10.1038/Sj.Onc.1205864 |
0.351 |
|
| 2001 |
Wang Y, Irish J, MacMillan C, Brown D, Xuan Y, Boyington C, Gullane P, Kamel-Reid S. High frequency of microsatellite instability in young patients with head-and-neck squamous-cell carcinoma: lack of involvement of the mismatch repair genes hMLH1 AND hMSH2. International Journal of Cancer. Journal International Du Cancer. 93: 353-60. PMID 11433399 DOI: 10.1002/Ijc.1337 |
0.333 |
|
| 2001 |
Bradley G, Irish J, MacMillan C, Mancer K, Witterick I, Hartwick W, Gullane P, Kamel-Reid S, Benchimol S. Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma. Oncogene. 20: 654-8. PMID 11313998 DOI: 10.1038/Sj.Onc.1204131 |
0.335 |
|
| 2001 |
Al-Maghrabi J, Kamel-Reid S, Jewett M, Gospodarowicz M, Wells W, Banerjee D. Primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type arising in the urinary bladder: report of 4 cases with molecular genetic analysis. Archives of Pathology & Laboratory Medicine. 125: 332-336. PMID 11231478 DOI: 10.1043/0003-9985(2001)125<0332:Plgbcl>2.0.Co;2 |
0.31 |
|
| 2000 |
Lichty BD, Kamel-Reid S. Exon-skipping in BCR/ABL is induced by ABL exon 2. Biochemical Journal. 348: 63-69. DOI: 10.1042/Bj3480063 |
0.334 |
|
| 1999 |
Hummel JL, Wells RA, Dubé ID, Licht JD, Kamel-Reid S. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene. 18: 633-41. PMID 9989813 DOI: 10.1038/Sj.Onc.1202357 |
0.319 |
|
| 1999 |
Rasul I, Shepherd FA, Kamel-Reid S, Krajden M, Pantalony D, Heathcote EJ. Detection of occult low‐grade B‐cell non‐hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia Hepatology. 29: 543-547. PMID 9918933 DOI: 10.1002/Hep.510290224 |
0.302 |
|
| 1998 |
Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G, Nwachukwu B, Kim P, Guo J, Kamel-Reid S. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia British Journal of Haematology. 103: 711-715. PMID 9858221 DOI: 10.1046/J.1365-2141.1998.01033.X |
0.321 |
|
| 1995 |
Lichty BD, Ackland-Snow J, Noble L, Kamel-Reid S, Dubé ID. Dysregulation of HOX11 by chromosome translocations in T-cell acute lymphoblastic leukemia: a paradigm for homeobox gene involvement in human cancer. Leukemia & Lymphoma. 16: 209-15. PMID 7719228 DOI: 10.3109/10428199509049759 |
0.312 |
|
| 1991 |
Kamel-Reid S, Letarte M, Doedens M, Greaves A, Murdoch B, Grunberger T, Lapidot T, Thorner P, Freedman MH, Phillips RA, Dick JE. Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice Blood. 78: 2973-2981. PMID 1835412 DOI: 10.1182/Blood.V78.11.2973.Bloodjournal78112973 |
0.305 |
|
| Show low-probability matches. |